Zacks Investment Research downgraded shares of Mereo BioPharma Group (NASDAQ:MREO) from a buy rating to a hold rating in a research report sent to investors on Wednesday morning, reports.

According to Zacks, “Mereo BioPharma Group PLC is a biopharmaceutical company. It is focused on development and commercialization of therapeutics for patients with rare diseases. The company’s product pipeline includes BPS-804, MPH-966, BCT-197, BGS-649, Navicixizumab and Etigilimab which are in clinical stage. Mereo BioPharma Group PLC is based in London, United Kingdom. “

MREO has been the topic of several other reports. Leerink Swann started coverage on Mereo BioPharma Group in a research note on Thursday, October 10th. They issued an outperform rating on the stock. Svb Leerink restated an outperform rating on shares of Mereo BioPharma Group in a research note on Thursday, October 10th.

Shares of MREO traded up $0.13 during mid-day trading on Wednesday, hitting $2.51. The stock had a trading volume of 16,900 shares, compared to its average volume of 20,118. The stock’s fifty day moving average price is $3.05. Mereo BioPharma Group has a 52 week low of $2.18 and a 52 week high of $8.48.

About Mereo BioPharma Group

Mereo BioPharma Group plc, a biopharmaceutical company, acquires, develops, and commercializes therapeutics for the treatment of rare and specialty diseases. Its product candidates include BPS-804, a novel antibody, which is in Phase IIb clinical trial for the treatment of osteogenesis imperfecta; MPH-966, an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency; BGS-649, an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism; and BCT-197, an oral p38 MAP kinase inhibitor that has completed Phase II clinical trial to treat acute exacerbations of chronic obstructive pulmonary disease.

Further Reading: What is the Fibonacci sequence?

Get a free copy of the Zacks research report on Mereo BioPharma Group (MREO)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Mereo BioPharma Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mereo BioPharma Group and related companies with's FREE daily email newsletter.